Who are Colchicine Pill's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Placebo, docetaxel, Cisplatin and Docetaxel, NK105, similar placebo to mebendazole, Abraxane (Maintenance), Carboplatin plus Paclitaxel.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/colchicine-pill.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Colchicine Pill — Competitive Intelligence Brief

Colchicine Pill (Colchicine Pill) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Microtubule inhibitor / Anti-inflammatory agent. Area: Rheumatology / Immunology.

marketed Microtubule inhibitor / Anti-inflammatory agent Beta-tubulin Rheumatology / Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Colchicine Pill (Colchicine Pill) — Brigham and Women's Hospital. Colchicine inhibits microtubule polymerization by binding to tubulin, thereby suppressing inflammatory cell migration and reducing production of inflammatory mediators.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Colchicine Pill TARGET	Colchicine Pill	Brigham and Women's Hospital	marketed	Microtubule inhibitor / Anti-inflammatory agent	Beta-tubulin
Placebo, docetaxel	Placebo, docetaxel	Akeso	phase 3	Taxane; microtubule stabilizer	Beta-tubulin
Cisplatin and Docetaxel	Cisplatin and Docetaxel	Swiss Cancer Institute	phase 3	Chemotherapy combination (platinum agent + taxane)	DNA (cisplatin); beta-tubulin (docetaxel)
NK105	NK105	Nippon Kayaku Co., Ltd.	phase 3	Microtubule inhibitor	Beta-tubulin
similar placebo to mebendazole	similar placebo to mebendazole	Swiss Tropical & Public Health Institute	phase 3	Anthelmintic	Beta-tubulin
Abraxane (Maintenance)	Abraxane (Maintenance)	Celgene	phase 3	Microtubule stabilizer (taxane)	Beta-tubulin / microtubules
Carboplatin plus Paclitaxel	Carboplatin plus Paclitaxel	The University of Hong Kong	phase 3	Chemotherapy combination (platinum agent + taxane)	DNA (carboplatin); beta-tubulin (paclitaxel)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Microtubule inhibitor / Anti-inflammatory agent class)

Azienda Sanitaria Locale 3, Torino · 3 drugs in this class
Brigham and Women's Hospital · 1 drug in this class
The George Institute · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Colchicine Pill — Competitive Intelligence Brief. https://druglandscape.com/ci/colchicine-pill. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab